8-K: Arbutus Biopharma Reports Q3 2024 Financial Results and Provides Clinical Development Update

Arbutus Biopharma announced its third quarter 2024 financial results, provided a corporate update, and highlighted progress in its clinical trials for chronic hepatitis B virus (cHBV) treatments.

Summary

• Arbutus Biopharma reported a net loss of $19.7 million for the third quarter of 2024, compared to a $20.1 million loss in the same period of 2023.
• The company's total revenue for the quarter was $1.3 million, a decrease from $4.7 million in the third quarter of 2023, primarily due to reduced licensing and royalty revenue.
• Research and development expenses decreased to $14.3 million from $20.2 million year-over-year, due to the discontinuation of certain programs.
• Arbutus had $130.8 million in cash, cash equivalents, and investments as of September 30, 2024, and expects its cash runway to extend into the fourth quarter of 2026.
• The company used $54.5 million in operating activities during the first nine months of 2024, partially offset by $44.1 million from share issuances and $6.1 million from stock option exercises.
• A one-time restructuring charge of $3.6 million was incurred in the third quarter due to the cessation of discovery efforts and a reduction in headcount.
• The company is advancing its imdusiran and AB-101 programs, with data from clinical trials to be presented at the AASLD meeting in November 2024.
• Arbutus is also involved in ongoing patent litigation against Moderna and Pfizer/BioNTech regarding their use of Arbutus' LNP technology.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to promising clinical trial results and a strong cash position, but tempered by decreased revenue and a net loss. The ongoing litigation also adds uncertainty.

Positives

• The company has a strong cash position with a runway into the fourth quarter of 2026.
• Clinical trial data for imdusiran shows promising results in achieving HBsAg loss and reducing viral load in cHBV patients.
• AB-101 is progressing well in clinical trials, demonstrating dose-dependent receptor occupancy.
• Arbutus is actively pursuing patent litigation to protect its intellectual property and seek compensation.
• The company is focused on advancing its core programs, imdusiran and AB-101, for a functional cure for cHBV.

Negatives

• The company experienced a decrease in revenue compared to the same period last year.
• Arbutus incurred a net loss of $19.7 million for the quarter.
• The company incurred a $3.6 million one-time restructuring charge.
• The company discontinued its coronavirus and AB-161 programs.

Risks

• Clinical trials may be more costly or take longer to complete than anticipated.
• The company may not receive necessary regulatory approvals for its products.
• Economic and market conditions may worsen, impacting the company's financial position.
• There are uncertainties associated with ongoing patent litigation.
• The company may experience additional employee turnover due to organizational changes.

Future Outlook

Arbutus expects to continue advancing its imdusiran and AB-101 programs, with preliminary data from the AB-101 trial expected in the first half of 2025. The company anticipates its cash runway will extend into the fourth quarter of 2026.

Management Comments

• Michael J. McElhaugh, Interim President and Chief Executive Officer, stated that they are making significant progress in advancing the development of imdusiran.
• Mr. McElhaugh also mentioned that the company is well-positioned to advance imdusiran into a Phase 2b clinical trial.
• Mr. McElhaugh noted that AB-101 is progressing well, with dose-dependent receptor occupancy observed.

Industry Context

Arbutus is operating in the competitive biopharmaceutical space focused on developing treatments for chronic hepatitis B virus (cHBV). The company's approach of combining RNAi therapeutics and immunomodulators aligns with the industry trend of seeking functional cures for chronic viral infections. The ongoing patent litigation highlights the importance of intellectual property in this sector.

Comparison to Industry Standards

• The reported HBsAg loss rates in the IM-PROVE I trial are competitive with other experimental HBV therapies, though direct comparisons are difficult due to varying trial designs and patient populations.
• The use of RNAi therapeutics like imdusiran is a growing area of interest in the HBV field, with companies like Arrowhead Pharmaceuticals also developing similar treatments.
• The development of oral PD-L1 inhibitors like AB-101 is a novel approach, as most checkpoint inhibitors are administered intravenously. This could offer a more convenient treatment option if successful.
• The company's cash runway into Q4 2026 is relatively strong compared to other clinical-stage biotechs, providing financial stability for ongoing research and development.
• The ongoing litigation against Moderna and Pfizer/BioNTech is a significant event, as it could potentially result in substantial financial compensation for Arbutus, similar to other cases where companies have successfully defended their intellectual property.

Legal Proceedings

• Arbutus is involved in ongoing patent litigation against Moderna and Pfizer/BioNTech regarding their use of Arbutus' LNP technology.
• A trial date has been set for September 24, 2025, for the Moderna lawsuit, subject to court availability.
• A claim construction hearing for the Pfizer/BioNTech lawsuit is scheduled for December 18, 2024.

Stakeholder Impact

• Shareholders may be impacted by the financial results and the progress of clinical trials.
• Employees may be affected by the organizational changes and headcount reductions.
• Patients with cHBV may benefit from the development of new treatment options.
• The outcome of the patent litigation could have a significant financial impact on the company and its stakeholders.

Next Steps

• Arbutus will present additional data from the IM-PROVE I and IM-PROVE II trials at the AASLD-The Liver Meeting 2024.
• The company will continue to advance the clinical development of imdusiran and AB-101.
• Arbutus will continue to pursue its patent litigation against Moderna and Pfizer/BioNTech.
• Preliminary data from the AB-101 trial is expected in the first half of 2025.

Key Dates

Keywords

Hepatitis B, cHBV, Imdusiran, AB-101, RNAi, PD-L1 Inhibitor, Clinical Trials, LNP Technology, Patent Litigation, Functional Cure